Kaiser Santa Clara Homestead Campus, Santa Clara, CA, USA.
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1381-4. doi: 10.1002/acr.21989.
To report our experience with the efficacy and safety of anakinra for acute gouty arthritis in medically complex hospitalized patients.
We reviewed the hospital charts of 26 patients treated with anakinra for crystal-induced arthritis since 2007. Demographics, comorbid conditions, reason for anakinra use, response to treatment, and any adverse outcomes were recorded.
Twenty-six patients received 40 courses of anakinra therapy. In 67% of patients, pain improved significantly within 24 hours, and complete resolution of signs and symptoms of gout occurred by day 5 in 72.5% of patients. Seven patients received multiple courses with no decrement in response with repeated treatments. Anakinra was well tolerated and no adverse outcomes were attributed to the medication. Only 1 patient appeared to be refractory to this form of interleukin-1 inhibition.
Anakinra is an effective and safe alternative treatment for acute gouty arthritis in medically complex hospitalized patients who fail or cannot undergo more conventional therapy.
报告我们在患有多种合并症的住院患者中使用阿那白滞素治疗急性痛风性关节炎的疗效和安全性经验。
我们回顾了自 2007 年以来使用阿那白滞素治疗晶体诱导性关节炎的 26 例患者的病历。记录了患者的人口统计学、合并症、使用阿那白滞素的原因、治疗反应以及任何不良结局。
26 例患者接受了 40 个疗程的阿那白滞素治疗。在 67%的患者中，疼痛在 24 小时内显著改善，72.5%的患者在 5 天内完全缓解痛风的体征和症状。7 例患者接受了多次治疗，重复治疗并未降低反应。阿那白滞素耐受性良好，没有不良反应归因于该药物。只有 1 例患者似乎对这种白细胞介素-1 抑制形式有抗性。
对于不能或不能接受更常规治疗的患有多种合并症的住院患者，阿那白滞素是治疗急性痛风性关节炎的一种有效且安全的替代治疗方法。
